{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:37Z","timestamp":1786986937029,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clinthera.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:45:13Z","timestamp":1684161913000},"page":"860-867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8924","authenticated-orcid":false,"given":"Andre Lucas","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Dullius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia Sarzi","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Azeredo-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Lubianca","family":"Kohem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odirlei Andr\u00e9","family":"Monticielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Palominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.04.005_bib0001","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. Published online May 28."},{"key":"10.1016\/j.clinthera.2023.04.005_bib0002","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0004","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3899\/jrheum.110687","article-title":"Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America","volume":"39","author":"Benegas","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42358-020-00161-5","article-title":"Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis","volume":"61","author":"Citera","year":"2021","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0006","article-title":"Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study","volume":"7","author":"L\u00f3pez-Medina","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/RHU.0000000000000515","article-title":"PANLAR presidency, first self-assessment report 2014-2016: challenges, opportunities, and results","volume":"23","author":"Pineda","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3899\/jrheum.111246","article-title":"Global partnering opportunities and challenges of psoriasis and psoriatic arthritis in Latin America: a report from the GRAPPA 2010 annual meeting","volume":"39","author":"Espinoza","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0009","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s10067-020-04934-7","article-title":"International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings","volume":"39","author":"Elmamoun","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0010","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/XEB.0000000000000062","article-title":"Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation","volume":"13","author":"Lockwood","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0012","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, et\u00a0al. Chapter 7: Systematic reviews of etiology and risk. 2020. JBI Manual for Evidence Synthesis. PublishedAccessed March 26, 2023 https:\/\/jbi-global-wiki.refined.site\/space\/MANUAL\/4687372\/Chapter+7%3A+Systematic+reviews+of+etiology+and+risk.","DOI":"10.46658\/JBIRM-17-06"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0013","doi-asserted-by":"crossref","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies","author":"Munn","year":"2019","journal-title":"JBI Database System Rev Implement Rep"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0014","first-page":"1","article-title":"Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional disease-modifying anti-rheumatic drugs in an endemic area","volume":"40","author":"Luis","year":"2020","journal-title":"Clin Biomedical Res"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0015","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212598","article-title":"Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country","volume":"9","author":"Chaer","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0016","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1590\/0074-02760150235","article-title":"Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline\u2014a longitudinal analysis after using TNFa blockers","volume":"110","author":"Gomes","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0017","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.6061\/clinics\/2020\/e1870","article-title":"Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area","volume":"75","author":"Shimabuco","year":"2020","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0018","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s10067-017-3714-6","article-title":"Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents","volume":"36","author":"Garziera","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00965","article-title":"Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting","volume":"10","author":"De Camargo","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semarthrit.2013.01.006","article-title":"Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases)","volume":"43","author":"Guedes-Barbosa","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0021","unstructured":"Sexto reporte de eventos adversos con tratamientos biol\u00f3gicos en Argentina: Informe del registro BIOBADASAR. Accessed March 16, 2023. http:\/\/www.scielo.org.ar\/scielo.php?script=sci_arttext&pid=S2362-36752019000100002"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0022","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3899\/jrheum.170520","article-title":"Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA study","volume":"45","author":"Bautista-Molano","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0023","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1590\/0102-311X00169514","article-title":"[Non-adherence to biological therapy in patients with rheumatic diseases in the Brazilian Unified National Health System in Minas Gerais State, Brazil]","volume":"31","author":"Dab\u00e9s","year":"2015","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0024","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10067-018-4383-9","article-title":"Treating psoriatic arthritis to target: discordance between physicians and patients\u2019 assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort","volume":"38","author":"Ferreira","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0025","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.18549\/PharmPract.2021.2.2312","article-title":"Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study","volume":"19","author":"Souza","year":"2021","journal-title":"Pharm Pract (Granada)"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0026","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10067-019-04870-1","article-title":"Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America","volume":"39","author":"Soriano","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42358-020-00131-x","article-title":"Home storage of biological medications administered to patients with rheumatic diseases","volume":"60","author":"Santin","year":"2020","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5152\/eurjrheum.2019.18182","article-title":"Survey on transportation and storage of biological therapies by patients","volume":"6","author":"Saavedra","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0029","first-page":"59","article-title":"Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation","author":"Da Silva","year":"2019","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0030","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/annrheumdis-2019-eular.5104","article-title":"Living with chronic inflammatory autoimmune disease in Brazil: the patient's perspective","volume":"78","author":"Ferreira","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0031","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/1744666X.2019.1631798","article-title":"Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations","volume":"15","author":"Da Silva","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PTT.S270621","article-title":"Frequency of health care resource utilization and direct medical costs associated with psoriatic arthritis in a rheumatic care center in Colombia","volume":"11","author":"Santos-Moreno","year":"2021","journal-title":"Psoriasis Targets Therapy"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0033","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.semarthrit.2021.05.020","article-title":"Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: analysis of the ASAS-perSpA study","volume":"51","author":"Zhao","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0034","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/rheumatology\/keab638","article-title":"Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study","volume":"61","author":"Capelusnik","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0035","unstructured":"Global tuberculosis report 2020. Accessed March 16, 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240013131"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0037","first-page":"785","article-title":"Epidemiology of endemic systemic fungal infections in Latin America","volume":"49","author":"Colombo","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/13693786.2012.714529","article-title":"Endemic paracoccidioidomycosis: relationship between clinical presentation and patients\u2019 demographic features","volume":"51","author":"Bellissimo-Rodrigues","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0039","unstructured":"Status of endemicity of cutaneous leishmaniasis. Accessed March 16, 2023. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/status-of-endemicity-of-cutaneous-leishmaniasis"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0041","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0042","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica (2011). Manual de recomenda\u00e7\u00f5es para o controle da tuberculose no Brasil. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/manual_recomendacoes_controle_tuberculose_brasil.pdf"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0043","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jps.21530","article-title":"Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality","volume":"98","author":"Carpenter","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0044","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-85413-0","article-title":"Thermolabile drug storage in an ambulatory setting","volume":"11","author":"do Pazo-Oubi\u00f1a","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0046","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/rheumatology\/kev394","article-title":"The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range","volume":"55","author":"Vlieland","year":"2016","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.04.005_bib0047","first-page":"31","article-title":"Assisted therapy model for dispensing immunobiological drugs for rheumatoid arthritis by the Brazilian Unified Health System: rational use of resources reduces expenses","volume":"14","author":"de Moraes","year":"2022","journal-title":"J Bras Econ Saude"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0048","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/cer-2019-0023","article-title":"Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database","volume":"8","author":"Oelke","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0049","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14740338.2020.1681396","article-title":"Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis","volume":"19","author":"Santoleri","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000585","article-title":"Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study","volume":"5","author":"Smolen","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171070","article-title":"Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?","volume":"12","author":"Pasma","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.04.005_bib0052","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10067-015-3018-7","article-title":"Access to an optimal treatment. Current situation","volume":"34 Suppl 1","author":"Ugarte-Gil","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0053","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1002\/hsr2.1034","article-title":"Impact of access to treatment on patient-reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin-American countries: A prospective observational study","volume":"6","author":"Reyes","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0054","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1089\/tmj.2019.0305","article-title":"Educational Intervention Using WhatsApp on Medication Adherence in Hypertension and Diabetes Patients: A Randomized Clinical Trial","volume":"26","author":"Sartori","year":"2020","journal-title":"Telemed J E Health"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fcdhc.2023.1132489","article-title":"Effectiveness of educational intervention in improving medication adherence among patients with diabetes in Klang Valley, Malaysia","volume":"4","author":"Atolagbe","year":"2023","journal-title":"Front Clin Diabetes Healthcare"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0056","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1353\/hpu.2011.0042","article-title":"Satisfaction with health care among Latinas","volume":"22","author":"Abra\u00eddo-Lanza","year":"2011","journal-title":"J Health Care Poor Underserved"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0057","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2105\/AJPH.93.10.1713","article-title":"Patient-physician relationships and racial disparities in the quality of health care","volume":"93","author":"Saha","year":"2003","journal-title":"Am J Public Health"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0058","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0059","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s10067-017-3578-9","article-title":"Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control","volume":"36","author":"Furst","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"10 Suppl","key":"10.1016\/j.clinthera.2023.04.005_bib0060","article-title":"Understanding the Hispanic\/Latino patient","volume":"124","author":"Caballero","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0061","first-page":"859","article-title":"Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Rubin","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0062","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-016-3549-5","article-title":"Benefit of health education by a training nurse in patients with axial and\/or peripheral psoriatic arthritis: a systematic literature review","volume":"36","author":"Candelas","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0063","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/annrheumdis-2020-218986","article-title":"2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice","volume":"80","author":"Ritschl","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0064","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00296-009-1358-9","article-title":"Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis","volume":"31","author":"Rodr\u00edguez-Polanco","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0065","first-page":"1218","article-title":"Treatment patterns with disease-modifying antirheumatic drugs in U.S. veterans with newly diagnosed rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"25","author":"Walsh","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0066","doi-asserted-by":"crossref","first-page":"E205","DOI":"10.9778\/cmajo.20150116","article-title":"Wait times to rheumatology care for patients with rheumatic diseases: a data linkage study of primary care electronic medical records and administrative data","volume":"4","author":"Widdifield","year":"2016","journal-title":"CMAJ Open"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0068","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0069","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"Van Nies","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12939-019-0960-z","article-title":"Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis","volume":"18","author":"Vargas-Pelaez","year":"2019","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0071","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1590\/S1020-49892013000300008","article-title":"[Right-to-health litigation in three Latin American countries: a systematic literature review]","volume":"33","author":"Reveiz","year":"2013","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0072","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s43441-020-00169-5","article-title":"A baseline analysis of regulatory review timelines for ANVISA: 2013-2016","volume":"54","author":"Patel","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0073","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s10067-020-05555-w","article-title":"Current status of the rheumatologists\u2019 workforce in Latin America: a PANLAR collaborative study","volume":"40","author":"Fern\u00e1ndez-\u00c1vila","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0074","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00393-017-0297-1","article-title":"[Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology\u2014update 2016]","volume":"76","author":"Zink","year":"2017","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.rdc.2018.09.002","article-title":"Workforce Trends in Rheumatology","volume":"45","author":"Kilian","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0076","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.reuma.2021.07.005","article-title":"The reality of Rheumatology in Spain and its autonomous communities before the pandemic","volume":"18","author":"S\u00e1nchez-Piedra","year":"2022","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0077","first-page":"8","article-title":"European Alliance of Associations for Rheumatology (EULAR) 2022 Congress","volume":"9","year":"2022","journal-title":"EMJ Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0078","first-page":"61","article-title":"Quality of referrals to a rheumatology service before and after implementation of a triage system with telemedicine support","author":"Piovesan","year":"2021","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0079","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3899\/jrheum.151235","article-title":"Triage of rheumatology referrals facilitates wait time benchmarks","volume":"43","author":"Farrer","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/annrheumdis-2011-201063","article-title":"A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis","volume":"72","author":"Villeneuve","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.04.005_bib0081","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2018-213464","article-title":"Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study","volume":"77","author":"Rodrigues Manica","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:17Z","timestamp":1758963617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0149291823001340"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.04.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}